Results 161 to 170 of about 53,515 (238)

Cabozantinib Monotherapy for Metastatic Renal Cell Carcinoma Involving Hemodialysis: Two Case Reports

open access: yesIJU Case Reports, Volume 9, Issue 6, November 2026.
ABSTRACT Introduction Data on cabozantinib monotherapy for metastatic renal cell carcinoma in patients requiring hemodialysis are scarce. We present two cases: initiation before hemodialysis with subsequent continuation and initiation during maintenance hemodialysis.
Taketoshi Nara   +6 more
wiley   +1 more source

Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. [PDF]

open access: yesClin Cancer Res
Borghaei H   +26 more
europepmc   +1 more source

The Efferocytosis‐Driven Macrophage Polarization: A Concerto in the Tumor Immunosuppressive Microenvironment

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Efferocytosis is a key process for macrophages to clear apoptotic cells, which undergoes the “ Find Me” chemotaxis signal stage, the “eat me” phagocytosis recognition stage and the “digest me” digestion stage in turn. During the aforementioned three stages, various signaling molecules released by apoptotic cells can promote the phenotypic polarization ...
Qiuping Chen   +3 more
wiley   +1 more source

A Pan‐Hepatic T‐Cell Atlas Identifies Disease‐Specific Immune Dysfunction and Therapeutic Targets for Immunotherapy

open access: yesMedComm, Volume 7, Issue 11, November 2026.
A Pan‐HEpatic single‐cell Atlas of T cells (Pheat) was constructed covering chronic hepatitis, cirrhosis, hepatocellular carcinoma (HCC), and healthy controls. CD8+ exhausted T cells (Tex) and CD4+ regulatory T cells (Treg) were delineated profound through decoding molecular and cellular variance, immune checkpoint networks, pathway analysis, and drug ...
Si‐Yuan Chen   +18 more
wiley   +1 more source

The Relationship Between Pre‐Operative Ipilimumab and Nivolumab Pharmacokinetics and Treatment Outcome in Locoregionally Advanced Urothelial Cancer

open access: yesClinical and Translational Science, Volume 19, Issue 11, November 2026.
ABSTRACT Patients with locoregionally advanced urothelial cancer (UC) received three pre‐operative cycles of ipilimumab and nivolumab in the NABUCCO trial, across three cohorts with different dosing combinations. This study aimed to define the pharmacokinetics (PK) of both drugs in this population and to assess the relationship between the PK and ...
Sybrand W. J. Zielhuis   +10 more
wiley   +1 more source

Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 11, Page 1566-1573, November 2026.
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo   +6 more
wiley   +1 more source

Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

open access: yes
PURPOSE: In NABUCCO, the safety and efficacy of preoperative ipilimumab plus nivolumab were assessed in stage III urothelial cancer. Encouraging responses were achieved, and ipilimumab 3 mg/kg (ipilimumab-high) seemed more effective than ipilimumab 1 mg ...
van Rhijn, Bas W G   +25 more
core  

Home - About - Disclaimer - Privacy